AMT prices IPO shares at 10 euros each

Amsterdam Molecular Therapeutics, a Dutch human gene therapy firm, says it will issue 5,000,000 new ordinary shares with a nominal value of 0.04 each euros for an offer price of 10.00 euros per share, subject to the satisfaction of certain conditions on the settlement date of the offering, which is expected to be on June 25.

Based on the final offer price and the issuance the offer price, AMT would have a market capitalization on commencement of tradings of approximately 139.0 million euros. Trading of the offer shares was expected to start at 11:00 am Amsterdam time on June 20.

AMT intends to use the proceeds of the IPO primarily for the development and commercialization of its products and to build a specialized marketing and sales team for Europe and North America capable of selling its lead product AMT-011, an investigational treatment for lipoprotein lipase deficiency. The agent has secured US and European orphan drug status for this indication.